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abstract
PURPOSE Asparaginase is an essential drug in childhood acute lymphoblastic leukemia (ALL) therapy and is
frequently given for months to obtain continuous asparagine depletion. We randomly assigned patients to
continuous versus intermittent pegylated-asparaginase (PEG-asp) treatment, hypothesizing there would be
decreased toxicity with unchanged efficacy.
METHODS Children (median age, 4.2 years) treated for non–high-risk ALL according to the Nordic Society for
Pediatric Hematology and Oncology ALL2008 protocol received five intramuscular PEG-asp injections (1,000
IU/m2) every two weeks and were then randomly assigned to additional three doses (6-week intervals [ex-
perimental arm], n = 309) versus 10 doses (2-week intervals [standard arm], n = 316). The primary end point
was noninferior (6% margin) disease-free survival. Toxicity reduction was a secondary end point. Occurrence of
asparaginase-associated hypersensitivity, pancreatitis, osteonecrosis, and thromboembolism were prospectively
registered.
RESULTS After a median follow-up of 4.1 years, the 5-year disease-free survival was 92.2% (95% CI, 88.6 to
95.8) and 90.8% (95% CI, 87.0 to 94.6) in the experimental and standard arms, respectively. The 3-year
cumulative incidence of any first asparaginase-associated toxicity (hypersensitivity [n = 13]; osteonecrosis
[n = 29]; pancreatitis [n = 24]; thromboembolism [n = 17]) was 9.3% in the experimental arm and 18.1% in
the standard arm (P = .001). Asparaginase-associated toxicity reduction was confirmed in sex- and
risk-group–adjusted Cox regression analysis stratified by age ($ 10 and , 10 years; hazard ratio, 0.48;
P = .001). The experimental arm had the lowest incidences of all four toxicities, reaching significance for
pancreatitis (6-month risk, 5.8% v 1.3%; P = .002).
CONCLUSION The excellent cure rates and reduced toxicity risk support the use of intermittent PEG-asp therapy
after the first 10 weeks in future childhood ALL trials that apply prolonged PEG-asp therapy.
J Clin Oncol 37:1638-1646. © 2019 by American Society of Clinical Oncology
INTRODUCTION
For decades, intensification of chemotherapy to im-
prove cure rates of childhood acute lymphoblastic
leukemia (ALL) has been a dominating strategy, but it
also increases the toxicity burden and treatment costs.
The overall survival rate of ALL now exceeds 90% in
the best contemporary programs,1-7 and the balance
between survival and toxicities has become critical.8
Asparagine is an essential amino acid for lympho-
blasts. Since the 1970s, the enzyme asparaginase has
played a key role in the treatment of ALL.9,10 Fur-
thermore, to fully exploit its potential, extended
asparaginase treatment up to 30 weeks has been
incorporated in many ALL protocols.11-14 However,
asparaginase also interferes with protein synthesis in
normal cells, and toxicities may necessitate discon-
tinuation of treatment and thus potentially increase
risk of relapse. We hypothesized that intermittent
pegylated-asparaginase (PEG-asp) treatment, similar
to the intermittent use of other antileukemic agents,
would not lead to an inferior disease-free survival
(DFS) compared with continuous administration, but
would significantly reduce the number of asparaginase-
associated toxicities.
PATIENTS AND METHODS
The ALL2008 protocol opened on July 1, 2008,
for patients with Philadelphia chromosome negative
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B-cell precursor or T-cell ALL. Included in the current study
were children (ages 1.0 to 17.9 years) with non–high-risk
ALL treated according to the Nordic Society for Pediatric
Hematology and Oncology (NOPHO) ALL2008 protocol in
Denmark, Finland, Iceland, Norway, or Sweden. Patients
were included from January 1, 2009, in Sweden and
Denmark; February 11, 2009, in Norway; June 1, 2009, in
Finland; and January 7, 2010, in Iceland. The randomi-
zation was closed on March 1, 2016, when all study pa-
tients who were still in the intensive PEG-asp arm shifted to
the intermittent arm, due to results obtained in interim
analysis (Data Supplement).
The randomization excluded patients with ALL pre-
disposition syndromes, previous cancer, chemotherapy
intolerance (eg, Charcot-Marie-Tooth disease, vincristine
intolerance), patients receiving more than 1 week of
treatment with antileukemic agents before diagnosis of ALL,
or incomplete registration of risk group–stratifying cytoge-
netic aberrations. The protocol was amended in November
2009 to exclude from random assignment patients with
t(12;21)[ETV6/RUNX1] and WBC count at diagnosis
greater than 100 3 109/L.
The protocol was approved by the National Medicines
Agencies (Eudract no. 2008-003235-20), relevant ethi-
cal committees, and registered at www.clinicaltrials.gov
(NCT00819351).
Treatment and Risk-Group Stratification
Risk grouping and therapy has been described in
detail2,15-17 (Data Supplement). All patients received
4 weeks of induction with vincristine, doxorubicin, and
glucocorticoids (ie, dexamethasone if T-cell ALL and/or
WBC count $ 100 3 109/L; otherwise prednisolone).
Non–high-risk patients were offered back-to-back partici-
pation in a randomization of fixed versus increasing doses
of 6-mercaptopurine during consolidation therapy (www.
clinicaltrials.gov: NCT00816049).18 The present random-
ization balanced this previous randomization but was
otherwise independent.
Asparaginase Treatment of Non–High-Risk Patients
and Randomization
PEG-asp 1,000 IU/m2/dose intramuscularly was given from
treatment day 30 until 33 weeks from diagnosis. All patients
received five doses at 2-week intervals during consolidation
therapy. For patients with hypersensitivity reactions to PEG-
asp, treatment was truncated, and subsequently they re-
ceived Erwinia asparaginase 20,000 IU/m2/dose three
times per week for 2 weeks during delayed intensification
and were not eligible for randomization, if this occurred
before randomization.
After consolidation therapy, patients were randomly
assigned to either 10 additional doses at 2-week intervals
(standard arm) or three additional doses at 6-week intervals
(experimental arm). In contrast to the standard arm,
patients in the experimental arm were not exposed to PEG-
asp during delayed intensification, when dexamethasone
was given for 2 weeks.
Enzyme Activity Measurements
Blood samples were supposed to be collected before each
PEG-asp dose for activity measurements. Results were not
reported to the clinicians. Patients randomly assigned to the
standard arm were to have samples taken 14 times, and
patients randomly assigned to the experimental arm,
seven times.
On the basis of enzyme activity measurements, patients
were considered to be asparagine depleted if they had
trough enzyme activity greater than 100 IU/L in samples
obtained 14 days 6 2 days after administration.19,20 Pa-
tients with fewer than four available samples during
treatment were categorized as asparagine depleted during
therapy if they had at least one activity measurement
greater than 100 IU/L provided before the fourth or
fifth dose.
Randomization Procedure
Block randomization was computer assigned (three
patients to each arm for every six patients randomly
assigned), stratification was by country, risk group, and
6-mercaptopurine randomization arm. The study was closed
March 1, 2016, when interim analyses showed significantly
reduced risk of asparaginase-associated toxicity in the ex-
perimental arm and that inclusion of the projected remaining
233 patients was unlikely to provide significant difference
in DFS (Data Supplement).
Capture of Asparaginase-Associated Toxicities and
Asparaginase Treatment Duration
Toxicities were captured or recaptured by several strate-
gies, including (1) quarterly prospective toxicity registration
of PEG-asp–associated hypersensitivity, osteonecrosis,
pancreatitis, and thromboembolism; (2) individual case-
report forms after discontinuation of PEG-asp treatment; (3)
detailed online registration of premature PEG-asp treat-
ment discontinuation (including date, reason, and number
of doses given); and (4) deep phenotyping studies of in-
dividual PEG-asp–associated toxicities (AspTox).15,21-28 If
toxicity information was inconsistent, the toxicities (in-
cluding dates of onset) were clarified by contacting the
treating centers.
Toxicities were defined as AspTox if they occurred during
PEG-asp or Erwinia asparaginase treatment, except for
osteonecrosis. Toxicities were categorized as being
asparaginase associated when they were identified up to
18 days after PEG-asp administration, when most patients
have been shown to have enzyme activity levels greater
than 100 IU/L after intramuscular administration.19 The
total number of PEG-asp doses was calculated as the
number of PEG-asp doses plus the number of Erwinia
asparaginase doses divided by six. Severity of pancreatitis
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and osteonecrosis was graded according to the Ponte di
Legno Toxicity definitions.29
Outcome Measures
The primary outcome was DFS with a noninferiority margin
of six percentage points between experimental and stan-
dard treatment arms. Accordingly, the study was designed
to enroll 429 patients in each arm and had an 83% power to
determine if the experimental arm was noninferior with
respect to relapse rate. Secondary outcome was any first
AspTox (ie, hypersensitivity, osteonecrosis, pancreatitis, or
thromboembolism). Sensitivity analyses included analysis
of toxicity-specific hazard ratios (HRs) instead of risks,
exclusion of patients with no enzyme activity, and adjust-
ment for risk group (only for any first toxicity), and sex and
stratification (because of nonproportional hazards) by age
group (1.0 to 9.9 years and 10.0 to 17.9 years). The ad-
justment variables were selected a priori. Interim analyses
were performed as part of the annual reporting to the Data
and Safety Monitoring Committee (DSMC) to comply with
Good Clinical Practice guidelines and assure safety. The
toxicity and relapse data in these DSMC reports were not
revealed to the treating clinicians.
Statistical Analysis
Study patients were followed from start of randomization
until the date of the first event (ie, relapse, death in first
remission, or second cancer), loss to follow-up or De-
cember 31, 2016, whichever came first. Comparison of
groups within each randomization arm was done by x2 test.
The follow-up time was estimated using the reverse Kaplan-
Meier method. DFS was estimated by the Kaplan-Meier
method, and noninferiority was evaluated on the basis of
the corresponding 95% CIs. Cumulative incidences of first
toxicity were estimated by the Aalen-Johansen estimator
considering relapse, death in first remission, and second
cancer as competing events, and the estimates per age-,
sex, and risk group were compared with Gray’s test. Cox
proportional-hazards model was used to estimate un-
adjusted, adjusted, and stratified toxicity-specific HRs with
significance evaluated with Wald tests. For the analyses of
time to specific toxicity, the patients were followed until the
date of the first specific toxicity, any competing event, or
18 days after the last PEG-asp dose. Two-sided P , 0.05
was considered statistically significant.
RESULTS
Of the 828 children (between 1.0 and 17.9 years old) who
were eligible for random assignment (Fig 1), 631 (76%)
were randomly assigned. The main reason for non-
randomization was parental refusal (80%).30 Subsequently,
six patients were excluded due to withdrawal of consent or
misinterpretation of randomization arm, leaving 309 and
316 patients randomly assigned to the experimental and
standard arms, respectively (Table 1). The 2015 annual
report to the DSMC showed almost identical DFS in the two
arms but significantly less AspTox in the experimental am.
The DSMC recommended closure of the randomization.
When the randomization closed on March 1, 2016, 15
patients treated according to the standard arm shifted to
the experimental arm, which is treated as a censoring event
in the analyses. None of these patients experienced an
event and only one had a toxicity (thromboembolism) after
randomization closure.
Disease-Free-Survival
After a median follow-up of 4.1 years (interquartile range
[IQR], 2.6–5.9) since date of randomization, four patients
had died during first remission (median, 0.4 years; IQR,
0.4–0.5), seven patients developed a second cancer
(median, 2.5 years; IQR, 2.0–3.6), and 30 developed
a relapse (median, 2.7 years; IQR, 1.5–3.7); 14 relapses
involved the CNS. The 5-year cumulative incidence of
relapse in the experimental and the standard armwas 6.6%
(95% CI, 3.3% to 10.0%) and 6.0% (95% CI, 2.9% to
9.1%), respectively (P = .81).
The 5-year DFS was 92.2% (95% CI, 88.6% to 95.8%) for
the experimental arm and 90.8% (95% CI, 87.0% to
94.6%) for the standard arm (Fig 2), thus not exceeding the
noninferiority limit of 6%. Adding the six randomly assigned
but noneligible patients did not make a noteworthy change
the outcome data.
Enzyme Activity Measurements
Most of the randomly assigned patients (n = 614 of 625;
98%) had sampling for activity measurements, allowing
580 patients to be classified as asparagine depleted during
treatment and with no significant difference of the distri-
bution of such patients between the two randomization
arms (P = .70; Data Supplement). Thirty-five of the 580
patients were categorized as asparagine depleted on the
basis of only one enzyme activity measurement taken late in
therapy (a median of8 weeks from initiation of PEG-asp;
experimental arm, n = 1; standard arm, n = 34); however,
we assumed they have been sufficiently exposed. Their
5-year DFS was 93.9% (95%CI, 85.8% to 100.0%). Among
the 34 patients with no enzyme activity at any measured
time point, the 5-year cumulative incidence of relapse was
15.8% (95% CI, 3.0% to 28.7%), compared with 5.9%
(95% CI, 3.5% to 8.2%) for the 580 asparagine-depleted
patients (P = .013), but the 5-year DFS did not significantly
differ between the two groups (84.2%; 95% CI, 71.3% to
97.0% v 91.8%; 95% CI, 89.0% to 94.5%, respectively;
P = .084). All relapses among the 34 patients involved the
bone marrow, including one in combination with CNS
relapse.
Asparaginase-Associated Toxicities
Fifteen patients were registered with a toxicity before the
start of the randomized treatment (two had pancreatitis and
13 had thromboembolism, equally divided between the two
arms), and these were not included in the toxicity summary.
1640 © 2019 by American Society of Clinical Oncology Volume 37, Issue 19
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Disregarding AspTox before randomization start, 60 pa-
tients experienced their first toxicity during PEG-asp
treatment and 23 after the last dose (13 had hypersensi-
tivity, 29 had osteonecrosis, 24 had pancreatitis, and 17
had thromboembolisms), with a median of 2.4 months
(IQR, 0.7624.80) until any first toxicity after start of the
randomized treatment (Data Supplement).
The 3-year cumulative incidence of any first AspTox after
randomization was significantly higher for children age
10 years or older (32.8%; 95% CI, 22.8% to 41.5%)
compared with children younger than 10 years (9.8%; 95%
CI, 7.2% to 12.3%; P , .001), but did not differ between
boys (13.0%; 95% CI, 9.2% to 16.7%) and girls (14.5%;
95% CI, 10.3% to 18.4%; P = .55) or between patients at
intermediate risk (15.3%; 95% CI, 10.6% to 19.8%) and
standard risk (12.7%; 95% CI, 9.2% to 16.0%; P = .42).
The 3-year cumulative incidence of any first AspTox after
start of randomized therapy was significantly lower for the
Patients invited to join study 
(N = 1,082)
Ineligible for random assignment      (n = 254)
   Death during induction           (n = 6)
   Missing stratifying data           (n = 8)
   Extra chemotherapy during induction       (n = 4)
   t(12;21) and WBC >100          (n = 16)
   Diagnosis before opening of          (n = 71)
      randomization
   Diagnosis after closure of          (n = 30)
      randomization
   Truncated asparaginase treatment        (n = 119)
      during consolidation
      Hypersensitivity          (n = 89)
      Pancreatitis           (n = 25) 
      Thromboembolism           (n = 5)
Eligible but not randomly assigned     (n = 197)
   Administrative reasons        (n = 6)*
   Clinical decision        (n = 24)†
   Parental refusal                    (n = 157)‡
   Other/missing info         (n = 10)
Patients eligible for random assignment 
(n = 828)
Patients randomly assigned 
(n = 631)
Patients allocated to intermittent Asp treatment
(n = 313)
Patients allocated to continuous Asp treatment
 (n = 318)
Randomly assigned but subsequently 
found ineligible                                           (n=4)
Withdrew consent                                          (n=4)
Randomly assigned but subsequently           (n = 2)
   found ineligible
   Withdrew consent                             (n = 1)
   Treated at 6 week intervals by mistake       (n = 1)
Patients included in the analyses
 (n = 309)
Patients included in the analyses
(n = 316)
FIG 1. Study profile. One thousand eighty-two Nordic children (age 1.0-17.9 years) with non-high risk (non-HR) acute lym-
phoblastic leukemia (ALL), either pre-B or T-cell, diagnosed from January 7, 2008, to February 29, 2016. WBC, white blood cell
count at diagnosis (3109); Asp, asparaginase. (p) Not randomly assigned, due to forgetfulness of the physician; (†) language or
communication problems; (‡) parents afraid of decrease of treatment or not wanting to participate in randomized studies in general.
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experimental arm (9.3%; 95% CI 6.0% to 12.6%) than for
the patients in the standard arm (18.1%; 95% CI, 13.74%
to 22.4%; P = .001; Fig 3).
The sex- and risk-group–adjusted, as well as age-
group–stratified toxicity-specific HR was significantly as-
sociated with the treatment (experimental arm, 0.48; 95%
CI, 0.30 to 0.75; P = .001), but not with sex (female, 1.16;
95% CI, 0.76 to 1.79; P = .49), or risk group (intermediate
risk, 0.95; 95% CI, 0.61 to 1.49; P = .83). The unadjusted
toxicity-specific HR remained significantly associated with
the treatment when including only the 328 boys in the
analyses (0.31; 95% CI, 0.15 to 0.62; 41 toxicities; P =
.001) or only the 518 children younger than 10 years (0.44;
95%CI, 0.24 to 0.79; 50 toxicities; P = .006), but not for the
297 girls (0.71; 95% CI, 0.38 to 1.31; 42 toxicities; P = .27)
or for the 107 children age 10 years or older (0.55; 95% CI,
0.27 to 1.12; 33 toxicities; P = .098; Fig 4). In the sensitivity
analysis including only the 580 patients with measurable
enzyme activity, the adjusted and stratified toxicity-specific
HRs showed the same pattern: experimental arm (0.54;
95% CI, 0.33 to 0.86; P = .009), female sex (1.11; 95% CI,
0.71 to 1.75; P = .64) and intermediate risk group (0.92;
95% CI, 0.57 to 1.47; P = .72).
Considering first individual AspTox, hypersensitivity (n = 13
patients), osteonecrosis (n = 35 patients, of whom 20 had
low-grade and 15 had high-grade osteonecrosis), pan-
creatitis (n = 22 patients, severe in 19), and thromboem-
bolism (n = 14 patients), the hazard rate and the
cumulative incidence of pancreatitis was significantly lower
in the experimental arm than in the standard arm (HR, 0.22
[95% CI, 0.073 to 0.64], P = .006; cumulative risk, 1.3% v
5.8%, P = .002), whereas it was nonsignificantly lower for
the other toxicities (Fig 4; Data Supplement). The sex-
adjusted and age-group stratified HRs showed similar re-
sults, as did the HRs from the sensitivity analyses including
only patients with enzyme activity (Data Supplement).
Asparaginase Treatment
The proportion of patients who received the full treatment of
15 or eight planned PEG-asp doses was significantly lower
for the standard arm (82%) than the experimental arm
(94%; P, .001; Data Supplement). Themedian number of
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FIG 2. The 5-year disease-free survival for the experimental arm was
92.2% (95% CI, 88.6 to 95.8) and for the standard arm was 90.8%
(95% CI, 87.0 to 94.6).
TABLE 1. Baseline Characteristics of Randomly Assigned Patients (n = 625)
Characteristic Intermittent Asparaginase (n = 309) Continuous Asparaginase (n = 316)
Sex
Male 159 (51) 169 (53)
Female 150 (49) 147 (47)
Age at diagnosis, median (range), years 4.0 (1.0-17.9) 4.5 (1.0-17.9)
Immunophenotype
BCP 290 (94) 290 (92)
T cell 19 (6) 26 (8)
Risk group
SR 189 (61) 193 (61)
IR 120 (39) 123 (39)
WBC count at diagnosis, median (range), 100 3 109/L 9.20 (0.40-394) 9.50 (0.7-825)
6-MP randomization during consolidation
Increments 134 (43) 136 (43)
Fixed 141 (46) 146 (46)
Eligible, not randomized 34 (11) 33 (11)
Not eligible — 1
NOTE. Data are given as No. (%) unless otherwise indicated.
Abbreviations: 6-MP, 6-mercaptopurine; BCP, B-cell precursor acute lymphoblastic leukemia; IR, intermediate risk; SR, standard risk.
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the total doses for patients with truncated treatment was
10 (range, 5 to 14) in the standard arm and six doses
(range, 5 to 7) in the experimental arm. The 68 patients with
truncated therapy due to AspTox did not have a 5-year DFS
that differed significantly from the remaining 557 patients
who received full asparaginase therapy according to
protocol (88.7%; 95%CI, 79.3 to 98.1 v 91.8%; 95 CI, 89.1
to 94.5; P = .43).
DISCUSSION
Intensification of chemotherapy has been the main strategy
to improve event-free survival for childhood ALL, but at
significant costs.1,5-7 For asparaginase, several studies have
supported that prolonged asparaginase treatment of
30 weeks increases DFS, not least by reducing the in-
cidence of relapse involving the CNS.31-33 This study
convincingly demonstrates that intermittent therapy as
given in ALL2008 provides significant reduction in AspTox
risk with no inferior DFS. In the present randomized study,
the cumulative incidence of relapse did not differ between
the two arms and beyond 5 years of follow-up, only one
relapse was diagnosed.
The recruitment to the current study was less than antic-
ipated, mostly because parents declined treatment re-
duction, fearing inferior treatment of the disease itself30.
The reduction of AspTox was most pronounced for pan-
creatitis, which is among the most burdensome compli-
cations of ALL therapy, and may be associated with
potentially lifelong severe morbidity. To facilitate the
comparison of various therapy-associated acute toxicities
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FIG 3. The 3-year cumulative incidence of any first asparaginase-
related toxicity was 9.3% (95% CI, 6.0 to 12.6) and 18.1% (95% CI,
13.74 to 22.4) in the experimental and standard arm, respectively
(P = .001).
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FIG 4. Forest plot showing the unadjusted hazard ratios (experimental v standard arm) for any first asparaginase-related toxicity after randomization start
and for each toxicity separately.
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between protocols, a worldwide initiative within the frame of
the Ponte di Legno Toxicity recently established consensus
definitions of toxicities associated with ALL therapy.29 The
phenotype of pancreatitis in ALL2008 has been described
in detail.22,23,34 This toxicity may potentially be life threat-
ening and may be followed by persistent pain as a result of
pseudocysts, and by chronic pancreatitis, insulin-
dependent diabetes mellitus, and impairment of the exo-
crine function.8,34,35
In NOPHO ALL2008, the cumulative risk of PEG-asp hy-
persensitivity was 13.2% and occurred after a median of
two doses (75% occurred between second and fourth
doses), which is comparable to reports from other
groups.11-13,21 Thus, the very few hypersensitivity reactions
observed in the current study primarily reflect that most of
the patients who were prone to develop this complication36
had already done so and thus become ineligible for
randomization.
The association between asparaginase therapy and
osteonecrosis remains uncertain, although hyperlipidemia
caused by the combination of asparaginase and gluco-
corticoids, not least dexamethasone (eg, during delayed
intensification), has been proposed as a risk factor.27 In this
study, patients in the experimental arm did not receive
PEG-asp during dexamethasone-containing delayed in-
tensification. However, the reduced frequency of osteo-
necrosis in the experimental arm did not reach statistical
significance. The occurrence of osteonecrosis in ALL2008
has been investigated in depth, and has a 5-year cumu-
lative incidence of 6.3%.26
Thromboembolism is a well-known complication during
cancer therapy.24,25,28,37-39 In ALL2008, the cumulative
incidence of thromboembolism is 6.1% (95% CI, 4.8% to
7.7%), including 2% risk of cerebral sinus venous
thrombosis, and occurring most frequently during PEG-asp
treatment.24,25,28 The lack of a significant association be-
tween randomization arm and the risk of thromboembolism
could reflect that predisposing host genome variants40 are
relatively more important for risk of thromboembolism and,
furthermore, that the low study power for this infrequent
toxicity so late in therapy.
Finally, hepatic sinusoidal obstruction syndrome has re-
cently been associated with PEG-asp treatment during
maintenance therapy.41 However, data on sinusoidal ob-
struction syndrome was not systematically captured for the
entire ALL2008 study cohort.
The duration of asparaginase treatment differs among tri-
als. Traditionally, Berlin-Frankfurt-Mu¨nster trials have used
much less asparaginase than what was given in the present
experimental arm,42 whereas Dana-Faber Cancer Institute
trials have used a duration similar to the ALL2008 standard
arm.12 Furthermore, Children’s Cancer Group showed that
the outcome in lower-risk patients was not correlated with
the number of doses of asparaginase received.43 In spite of
these differences in asparaginase therapy, the survival does
not vary between present protocols.1-7
PEG-asp treatment of patients with ALL is a considerable
health care cost. By reducing the number of doses from 15
to eight, the drug cost per patient is almost halved from
approximately $27.000 to 15.000 (prize provided by the
Danish Medicines Agency), to which is added the costs
associated with hospital admissions.
Historically, intensification of therapy by adding a delayed
intensification phase to low-risk patients resulted in better
event-free survival in the CCG-1881 trial,44 whereas other
randomized trials in line with the current study have shown
that intensification of chemotherapy may not result in
higher event-free survival rates,45,46 stressing that there is
a limit for achieving better survival results by increasing the
intensity of chemotherapy.
Our findings may reflect that maximum antileukemic effect
of PEG-asp has been provided during the first 10 weeks of
therapy. Although the observational studies that support
longer therapy do not support such a conclusion,11-14 the
results of an ongoing randomized trial comparing short
and extended PEG-asp therapy (www.clinicaltrials.gov:
NCT01117441) may clarify that issue.
In conclusion, the current study demonstrates that after the
first five doses of PEG-asp, additional PEG-asp at just
6-week intervals reduces toxicity and costs with equal ef-
ficacy compared with treatment every 2 weeks.
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